Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Bonesupport surges after CMS decision for CERAMENT G and expects strong growth
Bonesupport’s stock rose about 35% within a month, supported by improved reimbursement in the US from CMS for the antibiotic-containing bone substitute CERAMENT G. Analysts at ABG Sundal Collier expect an organic sales increase of 31% for Q1; results will be published on April 22. CEO Torbjörn Sköld confirms the 2026 guidance of more than 35% revenue growth, driven by further market penetration in foot/ankle, trauma and revision arthroplasty. Technically, the stock has moved above the 200-day moving average; investors are holding positions and betting on strong quarterly figures. » Mere på deraktionaer.de
Bonesupport targets at least 35% revenue growth in 2026 after strong Q4
Bonesupport reports a Q4 2025 revenue increase of 36% to SEK 313 million and records a sales increase of nearly 40% for 2025 overall. The company issues guidance for 2026 of at least 35% revenue growth at constant exchange rates and cites strong demand in the US for CERAMENT products as well as potential from indication expansions. Gross margins are typically around 90%; the stock rises by almost 20% after the outlook and reaches its highest level since October. » Mere på deraktionaer.de
Bonesupport records strong revenue and margin growth, shares fall after quarterly results
Bonesupport reported Q3 2025 net sales of SEK 294.1m (+24% yoy; +34% currency-adjusted) and an adjusted operating margin of 27%, driven by a strong US business and growth in the antibiotic-releasing CERAMENT products. Operating cash flow remained robust and net cash stood at SEK 379.0m at quarter-end. The company is preparing market entries in spine surgery and revision arthroplasty, received NTAP approval for CERAMENT G and reiterated full-year guidance of >40% currency-adjusted revenue growth. Despite operational progress, the stock fell sharply after the presentation, reflecting investor concerns about currency headwinds, possible regulatory hurdles and market risks. » Mere på de.investing.com
Bonesupport achieves record profitability and currency-adjusted revenue growth of 40% in Q2 2025
Bonesupport reports net sales of SEK 284m for Q2 2025 (+29% y/y; +40% currency-adjusted) and adjusted operating income of SEK 62m, the highest margin in the company’s history (EBIT margin 26%). The North American market drives growth (SEK 236m, +36% or +49% currency-adjusted), led by CERAMENT G with USD 18.3m in sales (+84%). Operating cash flow was SEK 50m; the company targets currency-adjusted revenue growth of over 40% for 2025 and plans to launch CERAMENT BVF for spinal applications in North America in December 2025. » Mere på de.investing.com
Bonesupport Holding AB reports strong revenue growth in the second quarter of 2025
Bonesupport Holding AB recorded a 29% increase in revenue to SEK 284.4 million in the second quarter of 2025, with a stable gross margin of around 95%. The US market showed particularly strong growth, with Cerement G sales rising by 84%, while the company reaffirmed its outlook for continued revenue growth. Despite regulatory and market challenges, the outlook remains positive, supported by product innovation and strategic expansion. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 36,06 mio. | 35,51 % |
| Bruttofortjeneste | 33,17 mio. | 34,18 % |
| Nettoresultat | 8,15 mio. | 160,94 % |
| EBITDA | 10,47 mio. | 68,69 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,86 mia. € |
Antal aktier | 65,22 mio. |
Højeste/laveste i 52 uger | 30,44 € - 15,03 € |
| Udbytte | Nej |
Beta | 0,49 |
P/E (PE Ratio) | 77,14 |
PEG (PEG Ratio) | 0,98 |
K/I (PB Ratio) | 20,98 |
P/S (PS Ratio) | 14,83 |
Virksomhedsprofil
Bonesupport Holding AB (publ), et ortobiologisk selskab, udvikler og kommercialiserer injicerbare bioceramiske knogletransplantatsubstitutter til behandling af knogledefekter i Europa, Nordamerika og internationalt. Selskabet leverer CERAMENT Bone Void Filler, en injicerbar, formbar og borbar syntetisk knogledefektfyldning, der indeholder hydroxyapatit, calciumsulfat og røntgenkontrastmidlet iohexol; CERAMENT G, et injicerbart keramisk knogletransplantatsubstitut med gentamicin; og CERAMENT V, en injicerbar syntetisk knogledefektfyldning med vancomycin. Selskabet udvikler desuden prækliniske produktkandidater, der skal fremme knoglevækst, med fokus på traumer, revisionsartroplastik, kronisk osteomyelitis, revisionsartroplastik og onkologi samt knogle- og fodinfektioner som følge af diabetes. Selskabet blev grundlagt i 1999 og har hovedkvarter i Lund, Sverige.
| Navn | Bonesupport Holding |
| CEO | Torbjorn Skold |
| Hjemsted | Lund,
sn Sverige |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 14.12.2017 |
| Medarbejdere | 160 |
Tickersymboler
| Børs | Symbol |
|---|---|
Sto | BONEX.ST |
London Stock Exchange | 0RQO.L |
XETRA | 2B4.F |
Pnk | BOEUF |
Frankfurt | 2B4.F |
Düsseldorf | 2B4.DU |
London | 0RQO.L |
Stockholm | BONEX.ST |
München | 2B4.MU |